108 related articles for article (PubMed ID: 24721293)
1. Improved detection of botulinum type E by rational design of a new peptide substrate for endopeptidase-mass spectrometry assay.
Rosen O; Feldberg L; Gura S; Zichel R
Anal Biochem; 2014 Jul; 456():50-2. PubMed ID: 24721293
[TBL] [Abstract][Full Text] [Related]
2. Optimization of SNAP-25-derived peptide substrate for improved detection of botulinum A in the Endopep-MS assay.
Rosen O; Feldberg L; Dor E; Gura S; Zichel R
Anal Biochem; 2017 Jul; 528():34-37. PubMed ID: 28450105
[TBL] [Abstract][Full Text] [Related]
3. A new peptide substrate for enhanced botulinum neurotoxin type B detection by endopeptidase-liquid chromatography-tandem mass spectrometry/multiple reaction monitoring assay.
Rosen O; Feldberg L; Gura S; Zichel R
Anal Biochem; 2015 Mar; 473():7-10. PubMed ID: 25277815
[TBL] [Abstract][Full Text] [Related]
4. Optimization of peptide substrates for botulinum neurotoxin E improves detection sensitivity in the Endopep-MS assay.
Wang D; Krilich J; Baudys J; Barr JR; Kalb SR
Anal Biochem; 2015 Jan; 468():15-21. PubMed ID: 25232998
[TBL] [Abstract][Full Text] [Related]
5. Sensitive detection of type G botulinum neurotoxin through Endopep-MS peptide substrate optimization.
Wang D; Baudys J; Hoyt K; Barr JR; Kalb SR
Anal Bioanal Chem; 2019 Aug; 411(21):5489-5497. PubMed ID: 31172236
[TBL] [Abstract][Full Text] [Related]
6. Further optimization of peptide substrate enhanced assay performance for BoNT/A detection by MALDI-TOF mass spectrometry.
Wang D; Baudys J; Hoyt KM; Barr JR; Kalb SR
Anal Bioanal Chem; 2017 Aug; 409(20):4779-4786. PubMed ID: 28573317
[TBL] [Abstract][Full Text] [Related]
7. Enhanced detection of type C botulinum neurotoxin by the Endopep-MS assay through optimization of peptide substrates.
Wang D; Krilich J; Baudys J; Barr JR; Kalb SR
Bioorg Med Chem; 2015 Jul; 23(13):3667-73. PubMed ID: 25913863
[TBL] [Abstract][Full Text] [Related]
8. Botulinum neurotoxin detection and differentiation by mass spectrometry.
Barr JR; Moura H; Boyer AE; Woolfitt AR; Kalb SR; Pavlopoulos A; McWilliams LG; Schmidt JG; Martinez RA; Ashley DL
Emerg Infect Dis; 2005 Oct; 11(10):1578-83. PubMed ID: 16318699
[TBL] [Abstract][Full Text] [Related]
9. Improved detection of botulinum neurotoxin serotype A by Endopep-MS through peptide substrate modification.
Wang D; Baudys J; Ye Y; Rees JC; Barr JR; Pirkle JL; Kalb SR
Anal Biochem; 2013 Jan; 432(2):115-23. PubMed ID: 23017875
[TBL] [Abstract][Full Text] [Related]
10. Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS.
Kalb SR; Garcia-Rodriguez C; Lou J; Baudys J; Smith TJ; Marks JD; Smith LA; Pirkle JL; Barr JR
PLoS One; 2010 Aug; 5(8):e12237. PubMed ID: 20808925
[TBL] [Abstract][Full Text] [Related]
11. Modification and validation of the Endopep-mass spectrometry method for botulinum neurotoxin detection in liver samples with application to samples collected during animal botulism outbreaks.
Tevell Åberg A; Karlsson I; Hedeland M
Anal Bioanal Chem; 2021 Jan; 413(2):345-354. PubMed ID: 33119784
[TBL] [Abstract][Full Text] [Related]
12. Development of a multiplex Endopep-MS assay for simultaneous detection of botulinum toxins A, B and E.
Rosen O; Feldberg L; Yamin TS; Dor E; Barnea A; Weissberg A; Zichel R
Sci Rep; 2017 Nov; 7(1):14859. PubMed ID: 29093524
[TBL] [Abstract][Full Text] [Related]
13. Studies on botulinum neurotoxins type /C1 and mosaic/DC using Endopep-MS and proteomics.
Moura H; Terilli RR; Woolfitt AR; Gallegos-Candela M; McWilliams LG; Solano MI; Pirkle JL; Barr JR
FEMS Immunol Med Microbiol; 2011 Apr; 61(3):288-300. PubMed ID: 21205003
[TBL] [Abstract][Full Text] [Related]
14. Improved detection of botulinum neurotoxin type A in stool by mass spectrometry.
Wang D; Baudys J; Kalb SR; Barr JR
Anal Biochem; 2011 May; 412(1):67-73. PubMed ID: 21276417
[TBL] [Abstract][Full Text] [Related]
15. The use of Endopep-MS for the detection of botulinum toxins A, B, E, and F in serum and stool samples.
Kalb SR; Moura H; Boyer AE; McWilliams LG; Pirkle JL; Barr JR
Anal Biochem; 2006 Apr; 351(1):84-92. PubMed ID: 16500606
[TBL] [Abstract][Full Text] [Related]
16. From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry.
Boyer AE; Moura H; Woolfitt AR; Kalb SR; McWilliams LG; Pavlopoulos A; Schmidt JG; Ashley DL; Barr JR
Anal Chem; 2005 Jul; 77(13):3916-24. PubMed ID: 15987092
[TBL] [Abstract][Full Text] [Related]
17. Recommended mass spectrometry-based strategies to identify botulinum neurotoxin-containing samples.
Kalb SR; Baudys J; Wang D; Barr JR
Toxins (Basel); 2015 May; 7(5):1765-78. PubMed ID: 25996606
[TBL] [Abstract][Full Text] [Related]
18. New highly specific botulinum type C1 endopeptidase immunoassays utilising SNAP25 or Syntaxin substrates.
Jones RG; Liu Y; Sesardic D
J Immunol Methods; 2009 Mar; 343(1):21-7. PubMed ID: 19176217
[TBL] [Abstract][Full Text] [Related]
19. Proposed BoNT/A and /B Peptide Substrates Cannot Detect Multiple Subtypes in the Endopep-MS Assay.
Kalb SR; Baudys J; Kiernan K; Wang D; Becher F; Barr JR
J Anal Toxicol; 2020 Mar; 44(2):173-179. PubMed ID: 31287544
[TBL] [Abstract][Full Text] [Related]
20. Rapid product analysis and increased sensitivity for quantitative determinations of botulinum neurotoxin proteolytic activity.
Rowe B; Schmidt JJ; Smith LA; Ahmed SA
Anal Biochem; 2010 Jan; 396(2):188-93. PubMed ID: 19782037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
